Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Accounts Payables · Q4 FY2025 · quarter ended Dec 2025
Accounts payables declines year over year
Q4 FY2025 accounts payables of $26K (cash outflow) fell 87.9% year over year.
Context
- Accounts payables increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 398K USD
- Year-over-year change
- +199.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 398K | +199.3% |
| FY2024 | 2024-12-31 | (401K) | -671.2% |
| FY2023 | 2023-12-31 | (52K) | — |
Accounts Payables vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's FY2025 accounts payables of $398K is the 7th largest of the 8 companies compared; the peer median is $6.37K.
- Its year-over-year change of +199.3% is the highest of 6, against a peer median of -49.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.81M | +112.4% | +48.6% | 13.8% | |
| LTM Mar 2026 | $2.84M | — | -35.9% | — | |
| LTM Mar 2026 | $1.7M | +135.6% | — | 5477.4% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $1.4M | — | — | — |
| LTM Mar 2026 | $793K | -49.2% | -33.2% | 2.8% | |
| LTM Mar 2026 | $457K | -171.4% | — | — | |
PLYXPolaryx Therapeutics, Inc. Common Stock | FY2025 | $398K | +199.3% | — | — |
| LTM Mar 2026 | $6.37K | -100.5% | — | 0.1% | |
| Peer median (excluding PLYX) | $6.37K | -49.2% | -33.2% | 8.3% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Depreciation & Amortization | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 3.24M | 2.4M | 0 |
| Change in Working Capital | 369K | (621K) | 316K |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | (52K) | (401K) | 398K |
| Other Working Capital | 421K | (220K) | (82K) |
| Other Non-Cash Items | 0 | 26M | 4.73M |
| Operating Cash Flow | (173K) | (2.57M) | (3.94M) |
| Capital Expenditures | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 |
| Debt Repayment | 128K | (128K) | 0 |
| Common Stock Issued | 0 | 7.32M | 4.47M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 128K | 7.19M | 4.47M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (45K) | 4.62M | 522K |
| Free Cash Flow | (173K) | (2.57M) | (3.94M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.